| Year |
Citation |
Score |
| 2021 |
Pearson JD, Huang K, Pacal M, McCurdy SR, Lu S, Aubry A, Yu T, Wadosky KM, Zhang L, Wang T, Gregorieff A, Ahmad M, Dimaras H, Langille E, Cole SPC, ... ... Knudsen ES, et al. Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. Cancer Cell. PMID 34270926 DOI: 10.1016/j.ccell.2021.06.016 |
0.391 |
|
| 2021 |
Witkiewicz AK, Cox D, Knudsen ES. Correction: CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes & Cancer. 12: 25-27. PMID 33884103 DOI: 10.18632/genesandcancer.211 |
0.381 |
|
| 2020 |
Kumarasamy V, Vail P, Nambiar R, Witkiewicz AK, Knudsen ES. Functional determinants of cell-cycle plasticity and sensitivity to CDK4/6 inhibition. Cancer Research. PMID 33323381 DOI: 10.1158/0008-5472.CAN-20-2275 |
0.459 |
|
| 2020 |
Franco J, Balaji U, Freinkman E, Witkiewicz AK, Knudsen ES. Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities. Cell Reports. 32: 107793. PMID 32640213 DOI: 10.1016/j.celrep.2020.107793 |
0.304 |
|
| 2020 |
Roberts PJ, Kumarasamy V, Witkiewicz AK, Knudsen ES. Chemotherapy and CDK4/6 inhibitors: Unexpected bedfellows. Molecular Cancer Therapeutics. PMID 32546660 DOI: 10.1158/1535-7163.Mct-18-1161 |
0.378 |
|
| 2020 |
Knudsen ES, Kumarasamy V, Chung S, Ruiz A, Vail P, Tzetzo S, Wu J, Nambiar R, Seshadri M, Abrams SI, Wang J, Witkiewicz AK. Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer. Gut. PMID 32424005 DOI: 10.1136/Gutjnl-2020-321000 |
0.311 |
|
| 2020 |
Knudsen ES, Shapiro GI, Keyomarsi K. Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 40: 115-126. PMID 32421454 DOI: 10.1200/EDBK_281085 |
0.415 |
|
| 2020 |
Knudsen ES, Nambiar R, Rosario SR, Smiraglia DJ, Goodrich DW, Witkiewicz AK. Pan-cancer molecular analysis of the RB tumor suppressor pathway. Communications Biology. 3: 158. PMID 32242058 DOI: 10.1038/s42003-020-0873-9 |
0.489 |
|
| 2020 |
Fountzilas C, Witkiewicz A, Muhitch J, Abrams S, Knudsen E, Mukherjee S, Bajor D, Saltzman J, Wang K, Iyer R, Kalinski P, Boland P. 103P Temporospatial heterogeneity in metastatic colorectal cancer (mCRC) Annals of Oncology. 31: S1458. DOI: 10.1016/j.annonc.2020.10.592 |
0.306 |
|
| 2019 |
Kumarasamy V, Ruiz A, Nambiar R, Witkiewicz AK, Knudsen ES. Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer. Oncogene. PMID 31745297 DOI: 10.1038/s41388-019-1102-1 |
0.416 |
|
| 2019 |
Knudsen ES, Pruitt SC, Hershberger PA, Witkiewicz AK, Goodrich DW. Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy. Trends in Cancer. 5: 308-324. PMID 31174843 DOI: 10.1016/j.trecan.2019.03.005 |
0.447 |
|
| 2019 |
Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, ... ... Knudsen ES, et al. Correction: Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Research. 79: 874. PMID 30770369 DOI: 10.1158/0008-5472.Can-18-4086 |
0.327 |
|
| 2019 |
Knudsen ES, Kumarasamy V, Ruiz A, Sivinski J, Chung S, Grant A, Vail P, Chauhan SS, Jie T, Riall TS, Witkiewicz AK. Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer. Oncogene. PMID 30696953 DOI: 10.1038/s41388-018-0650-0 |
0.387 |
|
| 2018 |
Chung S, Vail PJ, Witkiewicz AK, Knudsen ES. Coordinately targeting cell cycle checkpoint functions in integrated models of pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30538111 DOI: 10.1158/1078-0432.CCR-18-1620 |
0.357 |
|
| 2018 |
Knudsen ES, Zacksenhaus E. The vulnerability of RB loss in breast cancer: Targeting a void in cell cycle control. Oncotarget. 9: 30940-30941. PMID 30123416 DOI: 10.18632/oncotarget.25797 |
0.429 |
|
| 2018 |
Brough R, Gulati A, Haider S, Kumar R, Campbell J, Knudsen E, Pettitt SJ, Ryan CJ, Lord CJ. Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer. Oncogene. PMID 29915391 DOI: 10.1038/s41388-018-0368-z |
0.391 |
|
| 2018 |
Witkiewicz AK, Chung S, Brough R, Vail P, Franco J, Lord CJ, Knudsen ES. Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer. Cell Reports. 22: 1185-1199. PMID 29386107 DOI: 10.1016/j.celrep.2018.01.022 |
0.463 |
|
| 2017 |
Adams TA, Vail PJ, Ruiz A, Mollaee M, McCue PA, Knudsen ES, Witkiewicz AK. Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 28984302 DOI: 10.1038/modpathol.2017.126 |
0.488 |
|
| 2017 |
Knudsen ES, Hutcheson J, Vail P, Witkiewicz AK. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature. Oncotarget. PMID 28620137 DOI: 10.18632/Oncotarget.18435 |
0.416 |
|
| 2017 |
Knudsen ES, Witkiewicz AK. The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. Trends in Cancer. 3: 39-55. PMID 28303264 DOI: 10.1016/j.trecan.2016.11.006 |
0.31 |
|
| 2017 |
Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sanchez V, Ericsson PG, Sanders M, Pohlmann PR, Pishvaian MJ, Riddle DA, ... Knudsen E, et al. Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer. Cancer Research. PMID 28249908 DOI: 10.1158/0008-5472.Can-16-2653 |
0.363 |
|
| 2017 |
Knudsen E, Frankel A, Chang J, Witkiewicz A, Haley B. Palbociclib in combination with TDM1 for metastatic HER2+ breast cancer Annals of Oncology. 28: i7. DOI: 10.1093/ANNONC/MDX137.002 |
0.394 |
|
| 2016 |
Knudsen ES, Balaji U, Freinkman E, McCue P, Witkiewicz AK. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential. Oncotarget. PMID 27623078 DOI: 10.18632/Oncotarget.11893 |
0.403 |
|
| 2016 |
Knudsen ES, Witkiewicz AK. Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer. Oncotarget. PMID 27564114 DOI: 10.18632/oncotarget.11588 |
0.441 |
|
| 2016 |
Witkiewicz AK, Balaji U, Eslinger C, McMillan E, Conway W, Posner B, Mills GB, O'Reilly EM, Knudsen ES. Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer. Cell Reports. PMID 27498862 DOI: 10.1016/j.celrep.2016.07.023 |
0.337 |
|
| 2016 |
Hutcheson J, Balaji U, Porembka MR, Wachsmann MB, McCue PA, Knudsen ES, Witkiewicz AK. Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26858311 DOI: 10.1158/1078-0432.Ccr-15-1883 |
0.309 |
|
| 2016 |
Franco J, Balaji U, Freinkman E, Witkiewicz AK, Knudsen ES. Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities. Cell Reports. PMID 26804906 DOI: 10.1016/J.Celrep.2015.12.094 |
0.369 |
|
| 2015 |
Witkiewicz AK, Borja NA, Franco J, Brody JR, Yeo CJ, Mansour J, Choti MA, McCue P, Knudsen ES. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. Oncotarget. 6: 15788-801. PMID 26158861 DOI: 10.18632/Oncotarget.3819 |
0.422 |
|
| 2015 |
Hutcheson J, Witkiewicz AK, Knudsen ES. The RB tumor suppressor at the intersection of proliferation and immunity: relevance to disease immune evasion and immunotherapy. Cell Cycle (Georgetown, Tex.). 14: 3812-9. PMID 25714546 DOI: 10.1080/15384101.2015.1010922 |
0.341 |
|
| 2015 |
Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nature Reviews. Drug Discovery. 14: 130-46. PMID 25633797 DOI: 10.1038/nrd4504 |
0.325 |
|
| 2015 |
Knudsen ES, McClendon AK, Franco J, Ertel A, Fortina P, Witkiewicz AK. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer. Cell Cycle (Georgetown, Tex.). 14: 109-22. PMID 25602521 DOI: 10.4161/15384101.2014.967118 |
0.536 |
|
| 2015 |
Knudsen E, Franco J, Witkiewicz A. Targeting unique metabolic vulnerabilities in dormant ER+ tumor cells Annals of Oncology. 26: iii29. DOI: 10.1093/ANNONC/MDV120.03 |
0.328 |
|
| 2014 |
Baek G, Tse YF, Hu Z, Cox D, Buboltz N, McCue P, Yeo CJ, White MA, DeBerardinis RJ, Knudsen ES, Witkiewicz AK. MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. Cell Reports. 9: 2233-49. PMID 25497091 DOI: 10.1016/j.celrep.2014.11.025 |
0.331 |
|
| 2014 |
Witkiewicz AK, Knudsen ES. Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions. Breast Cancer Research : Bcr. 16: 207. PMID 25223380 DOI: 10.1186/bcr3652 |
0.529 |
|
| 2014 |
Witkiewicz AK, Cox D, Knudsen ES. CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes & Cancer. 5: 261-72. PMID 25221644 |
0.485 |
|
| 2014 |
Franco J, Witkiewicz AK, Knudsen ES. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget. 5: 6512-25. PMID 25156567 DOI: 10.18632/oncotarget.2270 |
0.365 |
|
| 2014 |
Hutcheson J, Bourgo RJ, Balaji U, Ertel A, Witkiewicz AK, Knudsen ES. Retinoblastoma protein potentiates the innate immune response in hepatocytes: significance for hepatocellular carcinoma. Hepatology (Baltimore, Md.). 60: 1231-40. PMID 24824777 DOI: 10.1002/Hep.27217 |
0.341 |
|
| 2014 |
Reed C, Hutcheson J, Mayhew CN, Witkiewicz AK, Knudsen ES. RB tumor suppressive function in response to xenobiotic hepatocarcinogens. The American Journal of Pathology. 184: 1853-9. PMID 24726645 DOI: 10.1016/J.Ajpath.2014.02.025 |
0.322 |
|
| 2014 |
Witkiewicz AK, Cox DW, Rivadeneira D, Ertel AE, Fortina P, Schwartz GF, Knudsen ES. The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer. Oncogene. 33: 3980-91. PMID 24121271 DOI: 10.1038/Onc.2013.367 |
0.76 |
|
| 2014 |
Knudsen E, Cox D, Franco J, Frankel A, Haley B, Witkiewicz A. Targeting CDK4/6 in Her2 Positive Breast Cancer: Therapeutic Effect, Markers, and Combination Strategies Annals of Oncology. 25: i21. DOI: 10.1093/ANNONC/MDU069.1 |
0.417 |
|
| 2013 |
Knudsen ES, Dervishaj O, Kleer CG, Pajak T, Schwartz GF, Witkiewicz AK. EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer. Cell Cycle (Georgetown, Tex.). 12: 2042-50. PMID 23759596 DOI: 10.4161/cc.25065 |
0.462 |
|
| 2013 |
Pestell R, Casimiro M, Crosariol M, Loro E, Dampier W, Sante GD, Ertel A, Yu Z, Saria E, Papanikolaou A, Li Z, Wang C, Addya S, Lisanti M, Fortina P, ... ... Knudsen E, et al. Abstract P5-07-06: Kinase-independent role of cyclin D1 in chromosomal instability and mammary tumorigenesis Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P5-07-06 |
0.372 |
|
| 2012 |
Knudsen ES, Pajak TF, Qeenan M, McClendon AK, Armon BD, Schwartz GF, Witkiewicz AK. Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progression. Journal of the National Cancer Institute. 104: 1825-36. PMID 23197489 DOI: 10.1093/jnci/djs446 |
0.404 |
|
| 2012 |
Witkiewicz AK, Ertel A, McFalls J, Valsecchi ME, Schwartz G, Knudsen ES. RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5110-22. PMID 22811582 DOI: 10.1158/1078-0432.CCR-12-0903 |
0.467 |
|
| 2012 |
Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, Knudsen ES. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle (Georgetown, Tex.). 11: 2756-61. PMID 22767154 DOI: 10.4161/cc.21195 |
0.518 |
|
| 2012 |
McClendon AK, Dean JL, Rivadeneira DB, Yu JE, Reed CA, Gao E, Farber JL, Force T, Koch WJ, Knudsen ES. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle (Georgetown, Tex.). 11: 2747-55. PMID 22751436 DOI: 10.4161/Cc.21127 |
0.747 |
|
| 2012 |
Dean JL, McClendon AK, Knudsen ES. Modification of the DNA damage response by therapeutic CDK4/6 inhibition. The Journal of Biological Chemistry. 287: 29075-87. PMID 22733811 DOI: 10.1074/jbc.M112.365494 |
0.326 |
|
| 2012 |
Knudsen ES, Ertel A, Davicioni E, Kline J, Schwartz GF, Witkiewicz AK. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. Breast Cancer Research and Treatment. 133: 1009-24. PMID 22134623 DOI: 10.1007/s10549-011-1894-3 |
0.445 |
|
| 2011 |
DelBove J, Rosson G, Strobeck M, Chen J, Archer TK, Wang W, Knudsen ES, Weissman BE. Identification of a core member of the SWI/SNF complex, BAF155/SMARCC1, as a human tumor suppressor gene. Epigenetics. 6: 1444-53. PMID 22139574 DOI: 10.4161/Epi.6.12.18492 |
0.434 |
|
| 2011 |
Bourgo RJ, Thangavel C, Ertel A, Bergseid J, McClendon AK, Wilkens L, Witkiewicz AK, Wang JY, Knudsen ES. RB restricts DNA damage-initiated tumorigenesis through an LXCXE-dependent mechanism of transcriptional control. Molecular Cell. 43: 663-72. PMID 21855804 DOI: 10.1016/J.Molcel.2011.06.029 |
0.319 |
|
| 2011 |
Witkiewicz AK, Knudsen KE, Dicker AP, Knudsen ES. The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle (Georgetown, Tex.). 10: 2497-503. PMID 21775818 DOI: 10.4161/Cc.10.15.16776 |
0.389 |
|
| 2011 |
Witkiewicz AK, Rivadeneira DB, Ertel A, Kline J, Hyslop T, Schwartz GF, Fortina P, Knudsen ES. Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment. The American Journal of Pathology. 179: 1171-8. PMID 21756866 DOI: 10.1016/J.Ajpath.2011.05.043 |
0.745 |
|
| 2011 |
McClendon AK, Dean JL, Ertel A, Fu Z, Rivadeneira DB, Reed CA, Bourgo RJ, Witkiewicz A, Addya S, Mayhew CN, Grimes HL, Fortina P, Knudsen ES. RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage. Gastroenterology. 141: 1439-50. PMID 21704587 DOI: 10.1053/J.Gastro.2011.06.046 |
0.706 |
|
| 2011 |
Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, Lin Z, Pavlides S, Wang C, Flomenberg N, Knudsen ES, Howell A, Pestell RG, Sotgia F, Lisanti MP. Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle (Georgetown, Tex.). 10: 1271-86. PMID 21512313 DOI: 10.4161/Cc.10.8.15330 |
0.446 |
|
| 2011 |
Witkiewicz AK, Knudsen ES. RB pathway and therapeutic sensitivity: new insights in breast cancer and Tamoxifen therapy. Cell Cycle (Georgetown, Tex.). 10: 1525. PMID 21502809 DOI: 10.4161/cc.10.10.15521 |
0.41 |
|
| 2011 |
Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, Witkiewicz AK, Clarke R, Knudsen ES. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocrine-Related Cancer. 18: 333-45. PMID 21367843 DOI: 10.1530/Erc-10-0262 |
0.456 |
|
| 2011 |
McClendon K, Dean JL, Rivadeneira D, Reed CA, Witkiewicz A, Gao E, Koch WJ, Force T, Knudsen ES. Abstract 591: Expanding the therapeutic window through pharmacological activation of the RB pathway in breast cancer treatment Cancer Research. 71: 591-591. DOI: 10.1158/1538-7445.Am2011-591 |
0.755 |
|
| 2011 |
Witkiewicz AK, Ertel A, Kline J, Davicioni E, Knudsen ES. Abstract 3906: Gene expression profiling of ductal carcinoma in situ reveals novel alterations in the tumor and stromal compartments related to progession and outcome of invasive breast cancer Cancer Research. 71: 3906-3906. DOI: 10.1158/1538-7445.Am2011-3906 |
0.375 |
|
| 2011 |
McClendon AK, Ertel A, Dean J, Thangavel C, Knudsen KE, Witkiewicz AK, Knudsen ES. Abstract 2982: Impact of the RB-pathway in breast cancer heterogeneity and therapeutic response Cancer Research. 71: 2982-2982. DOI: 10.1158/1538-7445.Am2011-2982 |
0.563 |
|
| 2011 |
Rivadeneira D, Mercier I, Lisanti MP, Witkiewicz A, Knudsen ES. Abstract 233: Crosstalk of Her2 signaling and cell cycle control in the response to targeted therapeutics in breast cancer Cancer Research. 71: 233-233. DOI: 10.1158/1538-7445.Am2011-233 |
0.778 |
|
| 2010 |
Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, Morrissey C, Zhang X, Comstock CE, Witkiewicz AK, Gomella L, Knudsen ES, Nelson PS, Knudsen KE. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. The Journal of Clinical Investigation. 120: 4478-92. PMID 21099110 DOI: 10.1172/Jci44239 |
0.438 |
|
| 2010 |
Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE, Knudsen ES. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle (Georgetown, Tex.). 9: 4153-63. PMID 20948315 DOI: 10.4161/Cc.9.20.13454 |
0.467 |
|
| 2010 |
Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, Wang C, Whitaker-Menezes D, Daumer KM, Lin Z, Witkiewicz AK, Flomenberg N, Howell A, Pestell RG, Knudsen ES, Sotgia F, et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle (Georgetown, Tex.). 9: 3256-76. PMID 20814239 DOI: 10.4161/Cc.9.16.12553 |
0.721 |
|
| 2010 |
Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene. 29: 4018-32. PMID 20473330 DOI: 10.1038/onc.2010.154 |
0.457 |
|
| 2010 |
Kuwahara Y, Charboneau A, Knudsen ES, Weissman BE. Reexpression of hSNF5 in malignant rhabdoid tumor cell lines causes cell cycle arrest through a p21(CIP1/WAF1)-dependent mechanism. Cancer Research. 70: 1854-65. PMID 20179200 DOI: 10.1158/0008-5472.Can-09-1922 |
0.302 |
|
| 2010 |
Knudsen ES, Wang JY. Targeting the RB-pathway in cancer therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1094-9. PMID 20145169 DOI: 10.1158/1078-0432.CCR-09-0787 |
0.479 |
|
| 2010 |
Burkhart DL, Ngai LK, Roake CM, Viatour P, Thangavel C, Ho VM, Knudsen ES, Sage J. Regulation of RB transcription in vivo by RB family members. Molecular and Cellular Biology. 30: 1729-45. PMID 20100864 DOI: 10.1128/Mcb.00952-09 |
0.335 |
|
| 2010 |
Rivadeneira DB, Mayhew CN, Thangavel C, Sotillo E, Reed CA, Graña X, Knudsen ES. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology. 138: 1920-30. PMID 20100483 DOI: 10.1053/J.Gastro.2010.01.007 |
0.726 |
|
| 2010 |
McClendon AK, Dean JL, Ertel A, Knudsen ES. Differential impact of tumor suppressor pathways on DNA damage response and therapy-induced transformation in a mouse primary cell model. Plos One. 5: e8558. PMID 20049321 DOI: 10.1371/journal.pone.0008558 |
0.433 |
|
| 2010 |
Fan Y, Boivin GP, Knudsen ES, Nebert DW, Xia Y, Puga A. The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Research. 70: 212-20. PMID 19996281 DOI: 10.1158/0008-5472.Can-09-3090 |
0.374 |
|
| 2010 |
Reed CA, Mayhew CN, McClendon AK, Knudsen ES. Unique impact of RB loss on hepatic proliferation: tumorigenic stresses uncover distinct pathways of cell cycle control. The Journal of Biological Chemistry. 285: 1089-96. PMID 19887370 DOI: 10.1074/jbc.M109.043380 |
0.373 |
|
| 2010 |
Dean JL, McClendon AK, Stengel KR, Knudsen ES. Modeling the effect of the RB tumor suppressor on disease progression: dependence on oncogene network and cellular context. Oncogene. 29: 68-80. PMID 19802012 DOI: 10.1038/onc.2009.313 |
0.447 |
|
| 2010 |
Rivadeneira D, Ertel A, Witkiewicz A, Mercier I, Lisanti M, Knudsen E. Abstract P4-01-04: The Impact of the Retinoblastoma Tumor Suppressor Pathway in Her2 Positive Breast Cancer Pathogenesis and Therapeutic Response Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P4-01-04 |
0.769 |
|
| 2010 |
Witkiewicz A, Kline J, Freydin B, Apanasovich T, Schwartz G, Knudsen E. Abstract P1-15-02: Impact of Retinoblastoma (RB) Tumor Suppressor Pathway on Ductal Carcinoma In Situ (DCIS) Recurrence Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P1-15-02 |
0.355 |
|
| 2009 |
Reed CA, Mayhew CN, McClendon AK, Yang X, Witkiewicz A, Knudsen ES. RB has a critical role in mediating the in vivo checkpoint response, mitigating secondary DNA damage and suppressing liver tumorigenesis initiated by aflatoxin B1. Oncogene. 28: 4434-43. PMID 19838213 DOI: 10.1038/onc.2009.303 |
0.376 |
|
| 2009 |
Millar EK, Dean JL, McNeil CM, O'Toole SA, Henshall SM, Tran T, Lin J, Quong A, Comstock CE, Witkiewicz A, Musgrove EA, Rui H, Lemarchand L, Setiawan VW, Haiman CA, ... ... Knudsen ES, et al. Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene. 28: 1812-20. PMID 19287456 DOI: 10.1038/Onc.2009.13 |
0.426 |
|
| 2009 |
Sotgia F, Del Galdo F, Casimiro MC, Bonuccelli G, Mercier I, Whitaker-Menezes D, Daumer KM, Zhou J, Wang C, Katiyar S, Xu H, Bosco E, Quong AA, Aronow B, Witkiewicz AK, ... ... Knudsen ES, et al. Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts. The American Journal of Pathology. 174: 746-61. PMID 19234134 DOI: 10.2353/Ajpath.2009.080658 |
0.486 |
|
| 2009 |
Sotgia F, Casimiro MC, Bonuccelli G, Liu M, Whitaker-Menezes D, Er O, Daumer KM, Mercier I, Witkiewicz AK, Minetti C, Capozza F, Gormley M, Quong AA, Rui H, Frank PG, ... ... Knudsen ES, et al. Loss of caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formation. The American Journal of Pathology. 174: 613-29. PMID 19164602 DOI: 10.2353/Ajpath.2009.080653 |
0.419 |
|
| 2009 |
Bourgo RJ, Braden WA, Wells SI, Knudsen ES. Activation of the retinoblastoma tumor suppressor mediates cell cycle inhibition and cell death in specific cervical cancer cell lines. Molecular Carcinogenesis. 48: 45-55. PMID 18506774 DOI: 10.1002/mc.20456 |
0.372 |
|
| 2008 |
Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. Nature Reviews. Cancer. 8: 714-24. PMID 19143056 DOI: 10.1038/Nrc2401 |
0.31 |
|
| 2008 |
Popowski M, Ferguson HA, Sion AM, Koller E, Knudsen E, Berg CLVD. Stress and IGF-I differentially control cell fate through mammalian target of rapamycin (mTOR) and retinoblastoma protein (pRB). Journal of Biological Chemistry. 283: 28265-28273. PMID 18697743 DOI: 10.1074/Jbc.M805724200 |
0.361 |
|
| 2008 |
Wang Y, Dean JL, Millar EK, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE, Knudsen ES. Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Research. 68: 5628-38. PMID 18632615 DOI: 10.1158/0008-5472.Can-07-3170 |
0.44 |
|
| 2008 |
Mercier I, Casimiro MC, Wang C, Rosenberg AL, Quong J, Minkeu A, Allen KG, Danilo C, Sotgia F, Bonuccelli G, Jasmin JF, Xu H, Bosco E, Aronow B, Witkiewicz A, ... ... Knudsen ES, et al. Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy Cancer Biology and Therapy. 7: 1212-1225. PMID 18458534 DOI: 10.4161/Cbt.7.8.6220 |
0.48 |
|
| 2008 |
Stengel KR, Dean JL, Seeley SL, Mayhew CN, Knudsen ES. RB status governs differential sensitivity to cytotoxic and molecularly-targeted therapeutic agents. Cell Cycle (Georgetown, Tex.). 7: 1095-103. PMID 18414045 DOI: 10.4161/cc.7.8.5737 |
0.339 |
|
| 2008 |
Peng L, Mayhew CN, Schnekenburger M, Knudsen ES, Puga A. Repression of Ah receptor and induction of transforming growth factor-beta genes in DEN-induced mouse liver tumors. Toxicology. 246: 242-7. PMID 18282651 DOI: 10.1016/J.Tox.2008.01.002 |
0.368 |
|
| 2007 |
Zagorski WA, Knudsen ES, Reed MF. Retinoblastoma deficiency increases chemosensitivity in lung cancer. Cancer Research. 67: 8264-73. PMID 17804741 DOI: 10.1158/0008-5472.Can-06-4753 |
0.41 |
|
| 2007 |
Reed MF, Zagorski WA, Knudsen ES. RB activity alters checkpoint response and chemosensitivity in lung cancer lines. The Journal of Surgical Research. 142: 364-72. PMID 17640669 DOI: 10.1016/J.Jss.2007.03.038 |
0.361 |
|
| 2007 |
Sharma A, Comstock CE, Knudsen ES, Cao KH, Hess-Wilson JK, Morey LM, Barrera J, Knudsen KE. Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Research. 67: 6192-203. PMID 17616676 DOI: 10.1158/0008-5472.Can-06-4424 |
0.423 |
|
| 2007 |
Srinivasan SV, Mayhew CN, Schwemberger S, Zagorski W, Knudsen ES. RB loss promotes aberrant ploidy by deregulating levels and activity of DNA replication factors. The Journal of Biological Chemistry. 282: 23867-77. PMID 17556357 DOI: 10.1074/jbc.M700542200 |
0.304 |
|
| 2007 |
Bosco EE, Knudsen ES. RB in breast cancer: at the crossroads of tumorigenesis and treatment. Cell Cycle (Georgetown, Tex.). 6: 667-71. PMID 17361100 DOI: 10.4161/cc.6.6.3988 |
0.554 |
|
| 2007 |
Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, Lowe SW, Knudsen ES. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. The Journal of Clinical Investigation. 117: 218-28. PMID 17160137 DOI: 10.1172/Jci28803 |
0.587 |
|
| 2007 |
Seeley SL, Bosco EE, Kramer E, Parysek LM, Knudsen ES. Distinct roles for RB loss on cell cycle control, cisplatin response, and immortalization in Schwann cells. Cancer Letters. 245: 205-17. PMID 16574317 DOI: 10.1016/J.Canlet.2006.01.028 |
0.396 |
|
| 2006 |
Knudsen ES, Sexton CR, Mayhew CN. Role of the retinoblastoma tumor suppressor in the maintenance of genome integrity. Current Molecular Medicine. 6: 749-57. PMID 17100601 DOI: 10.2174/1566524010606070749 |
0.408 |
|
| 2006 |
Knudsen ES, Knudsen KE. Retinoblastoma tumor suppressor: where cancer meets the cell cycle. Experimental Biology and Medicine (Maywood, N.J.). 231: 1271-81. PMID 16816134 DOI: 10.1177/153537020623100713 |
0.427 |
|
| 2006 |
Reed MF, Zagorski WA, Howington JA, Zilfou JT, Knudsen ES. Inhibition of retinoblastoma tumor suppressor activity by RNA interference in lung cancer lines. The Annals of Thoracic Surgery. 82: 249-53. PMID 16798224 DOI: 10.1016/J.Athoracsur.2006.02.033 |
0.321 |
|
| 2006 |
Knudsen E. Editorial [Hot Topic: The RB-Pathway in Cancer (Executive Editor: Erik Knudsen)] Current Molecular Medicine. 6: 703-704. DOI: 10.2174/1566524010606070703 |
0.334 |
|
| 2006 |
Reed M, Zagorski W, Dhamija A, Knudsen E. Inhibition of RB tumor suppressor activity increases chemosensitivity in lung cancer xenografts Journal of Surgical Research. 130: 291. DOI: 10.1016/J.Jss.2005.11.376 |
0.374 |
|
| 2005 |
Bosco EE, Knudsen ES. Differential role of RB in response to UV and IR damage. Nucleic Acids Research. 33: 1581-92. PMID 15767283 DOI: 10.1093/Nar/Gki283 |
0.305 |
|
| 2004 |
Mayhew CN, Perkin LM, Zhang X, Sage J, Jacks T, Knudsen ES. Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents. Oncogene. 23: 4107-20. PMID 15064736 DOI: 10.1038/Sj.Onc.1207503 |
0.357 |
|
| 2003 |
Angus SP, Solomon DA, Kuschel L, Hennigan RF, Knudsen ES. Retinoblastoma Tumor Suppressor: Analyses of Dynamic Behavior in Living Cells Reveal Multiple Modes of Regulation Molecular and Cellular Biology. 23: 8172-8188. PMID 14585976 DOI: 10.1128/Mcb.23.22.8172-8188.2003 |
0.309 |
|
| 2003 |
Knudsen ES, Angus SP. Functional analysis of the antimitogenic activity of tumor suppressors. Methods in Molecular Biology (Clifton, N.J.). 218: 3-15. PMID 12616708 DOI: 10.1385/1-59259-356-9:03 |
0.402 |
|
| 2002 |
Angus SP, Wheeler LJ, Ranmal SA, Zhang X, Markey MP, Mathews CK, Knudsen ES. Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication. The Journal of Biological Chemistry. 277: 44376-84. PMID 12221087 DOI: 10.1074/Jbc.M205911200 |
0.359 |
|
| 2002 |
Heinen CD, Goss KH, Cornelius JR, Babcock GF, Knudsen ES, Kowalik T, Groden J. The APC tumor suppressor controls entry into S-phase through its ability to regulate the cyclin D/RB pathway. Gastroenterology. 123: 751-63. PMID 12198702 DOI: 10.1053/Gast.2002.35382 |
0.398 |
|
| 2002 |
Betz BL, Strobeck MW, Reisman DN, Knudsen ES, Weissman BE. Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB. Oncogene. 21: 5193-203. PMID 12149641 DOI: 10.1038/Sj.Onc.1205706 |
0.385 |
|
| 2002 |
Reisman DN, Strobeck MW, Betz BL, Sciariotta J, Funkhouser W, Murchardt C, Yaniv M, Sherman LS, Knudsen ES, Weissman BE. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene. 21: 1196-207. PMID 11850839 DOI: 10.1038/sj.onc.1205188 |
0.316 |
|
| 2002 |
Strobeck MW, Reisman DN, Gunawardena RW, Betz BL, Angus SP, Knudsen KE, Kowalik TF, Weissman BE, Knudsen ES. Compensation of BRG-1 function by Brm: insight into the role of the core SWI-SNF subunits in retinoblastoma tumor suppressor signaling. The Journal of Biological Chemistry. 277: 4782-9. PMID 11719516 DOI: 10.1074/Jbc.M109532200 |
0.352 |
|
| 2000 |
Strobeck MW, Knudsen KE, Fribourg AF, DeCristofaro MF, Weissman BE, Imbalzano AN, Knudsen ES. BRG-1 is required for RB-mediated cell cycle arrest. Proceedings of the National Academy of Sciences of the United States of America. 97: 7748-53. PMID 10884406 DOI: 10.1073/Pnas.97.14.7748 |
0.376 |
|
| 2000 |
Strobeck MW, Fribourg AF, Puga A, Knudsen ES. Restoration of retinoblastoma mediated signaling to Cdk2 results in cell cycle arrest Oncogene. 19: 1857-1867. PMID 10773875 DOI: 10.1038/Sj.Onc.1203510 |
0.327 |
|
| 2000 |
Puga A, Barnes SJ, Dalton TP, Chang Cy, Knudsen ES, Maier MA. Aromatic hydrocarbon receptor interaction with the retinoblastoma protein potentiates repression of E2F-dependent transcription and cell cycle arrest. The Journal of Biological Chemistry. 275: 2943-50. PMID 10644764 DOI: 10.1074/Jbc.275.4.2943 |
0.364 |
|
| 1999 |
Knudsen KE, Weber E, Arden KC, Cavenee WK, Feramisco JR, Knudsen ES. The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. Oncogene. 18: 5239-45. PMID 10498874 DOI: 10.1038/Sj.Onc.1202910 |
0.417 |
|
| 1997 |
Arap W, Knudsen E, Sewell DA, Sidransky D, Wang JY, Huang HJ, Cavenee WK. Functional analysis of wild-type and malignant glioma derived CDKN2Abeta alleles: evidence for an RB-independent growth suppressive pathway. Oncogene. 15: 2013-20. PMID 9366518 DOI: 10.1038/Sj.Onc.1201389 |
0.307 |
|
| Show low-probability matches. |